Precision Radiation Therapy Yields Rare Success for Liver Tumors
Liver Tumor Treatment
Shaped-beam radiation therapy is a promising treatment for life-threatening metastatic liver tumors, according to researchers at the University of Rochester Medical Center who report an 88 percent success rate for controlling the lesions. This is the first evidence that doctors can treat these tumors with radiation, and the results doubled the average length of survival.
"Radiation therapy has not been a recommended treatment for liver metastases because of the poor results when whole-liver radiation was used," said Alan Katz, M.D., M.P.H. lead researcher and assistant professor of Radiation Oncology. "High-dose, precision radiation therapy is proving to be a promising therapy for metastatic liver disease and provides an effective treatment options for patients who previously didn't have any."
Radiation oncologists at the University's James P. Wilmot Cancer Center are leading the effort to expand shaped-beam radiation therapy, originally designed to treat brain tumors, to target metastatic liver tumors with pinpoint accuracy. Initial treatment results were presented today at the American Society for Therapeutic Radiology and Oncology's annual meeting in Denver.
Many forms of cancer are treated with radiation therapy, but tumors in the liver are difficult to target using conventional techniques because the organ moves during breathing. Shaped-beam radiation therapy, also known as stereotactic body radiation therapy, has expanded treatment options by delivering a high dose of radiation precisely to the tumor, while limiting the damage to healthy tissue surrounding the tumor.
In Rochester, doctors treated 72 patients with metastatic liver lesions between April 2001 and October 2004. Most of the patients had colorectal, breast, pancreatic, lung, genitourinary, esophageal and ovarian cancers, which had spread to the liver. The patients had a median of two lesions that ranged from 0.5 centimeters to 12.2 centimeters in diameter.
Doctors followed the patients' progress for an average of a year, though some were followed as long as three years, and the average survival was 13 months.